siRNA-SCD1 reduced the increase in intracellular TG levels (Figure 2C) and the accumulation of lipid droplets (Figure 2D, 2E) induced by sodium palmitate, indicating that inhibition of SCD1 activity can ameliorate hepatic steatosis in sodium palmitate-treated hepatocytes. This evidence concerns the gene SCD and fatty liver disease.